Sarepta Therapeutics Inc
$ 16.78
0.00%
07 Aug - close price
- Market Cap 1,772,422,000 USD
- Current Price $ 16.78
- High / Low $ 17.26 / 16.47
- Stock P/E N/A
- Book Value 14.46
- EPS -1.57
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE -0.09 %
- 52 Week High 25.32
- 52 Week Low 14.68
About
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$22.09
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-02-25 | 2025-11-03 | 2025-08-06 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-01 | 2024-02-28 | 2023-11-01 |
| Reported EPS | 0.42 | 3.16 | -3.58 | -0.13 | 2.02 | -3.42 | 1.9 | 0.62 | 0.44 | 0.73 | 0.47 | 0.37 |
| Estimated EPS | 0.34 | 1.05 | -1.05 | -0.37 | 1.16 | -0.65 | 2.0603 | 0.37 | 0.47 | 0.41 | 0.01 | -0.49 |
| Surprise | 0.08 | 2.11 | -2.53 | 0.24 | 0.86 | -2.77 | -0.1603 | 0.25 | -0.03 | 0.32 | 0.46 | 0.86 |
| Surprise Percentage | 23.5294% | 200.9524% | -240.9524% | 64.8649% | 74.1379% | -426.1538% | -7.7804% | 67.5676% | -6.383% | 78.0488% | 4600% | 175.5102% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SRPT
2026-08-08 11:10:40
Sarepta Therapeutics has appointed Michael Severino as its new Chief Executive Officer and a member of its Board of Directors. Severino, with a strong background in senior leadership and research in biotech, joins the company as it navigates a revenue reset, with Q2 2026 revenue down and narrowed 2026 guidance. Investors will be closely watching Severino's approach to gene therapy execution, ELEVIDYS safety management, and resource allocation across various programs, with his first full quarter as CEO serving as a key indicator of his strategy.
2026-08-07 21:10:40
State Street Corporation and its affiliate SSGA Funds Management, Inc. have reported a significant beneficial ownership stake in Sarepta Therapeutics (SRPT) through a Schedule 13G filing. State Street and related entities beneficially own 8.4% of Sarepta's common stock, totaling 8,916,103 shares, with shared voting power over 8,642,126 shares. Separately, SSGA Funds Management, Inc. holds a 6% beneficial ownership, comprising 6,285,547 shares.
2026-08-06 23:41:54
Sarepta Therapeutics (SRPT) shares rose 5% after its Q2 2026 earnings report, despite a significant revenue drop, due to the company reporting positive GAAP operating income and tightening its full-year guidance. Investors see this as confirmation of the company's path to profitability, transitioning from a single-product focus to a broader Duchenne-funding base. However, bears highlight ongoing concerns regarding capacity, safety events, and timing risks for ELEVIDYS, which could hinder revenue growth in the short term.
2026-08-06 21:10:40
Empowered Funds LLC significantly increased its stake in Sarepta Therapeutics (NASDAQ:SRPT) by 1,898,816.7% in Q1, holding 113,935 shares valued at $2.48 million. Other institutional investors also adjusted their positions, and collective institutional ownership stands at 86.68%. Despite the company beating Q2 earnings and revenue estimates, its revenue declined 34.3% year-over-year, leading to mixed analyst ratings and a consensus "Hold" with an average price target of $24.72.
2026-08-06 17:40:59
Sarepta Therapeutics (SRPT) reported Q2 2026 adjusted earnings and total revenues that beat analyst estimates, despite a significant year-over-year decline in both figures, primarily due to lower Elevidys sales. The company updated its 2026 net product revenue guidance and raised its collaboration and other revenues forecast, while narrowing its combined R&D and SG&A expense guidance. Sarepta is also advancing key pipeline programs, including seeking full FDA approvals for Vyondys 53 and Amondys 45 and progressing studies for other muscular dystrophy treatments.
2026-08-06 15:40:59
Sarepta Therapeutics' new CEO, Michael Severino, is navigating critical upcoming milestones that will determine the company's growth trajectory, including regulatory decisions for its Duchenne muscular dystrophy gene therapy Elevidys and exon-skipping treatments. Elevidys sales saw a sequential drop, though patient enrollment forms are increasing, and the company expects revenue improvements to lag until 2027. Severino also faces a pivotal FDA decision for Vyondys 53 and Amondys 45, and competition from Dyne Therapeutics' zeleciment rostudirsen.
